Chronic Myeloid Neoplasms
Myelodysplastic syndromes
Therapy related myelodysplastic syndrome

Author: Nikhil Sangle, M.D. (see Authors page)

Revised: 2 March 2017, last major update August 2011

Copyright: (c) 2002-2017, PathologyOutlines.com, Inc.

PubMed Search: Therapy related myelodysplastic syndrome [title]

See also: Alkylating agents causing therapy related MDS, Topoisomerase II inhibitors causing therapy related MDS
Cite this page: Therapy related myelodysplastic syndrome. PathologyOutlines.com website. http://pathologyoutlines.com/topic/myeloproliferativetherapyMDS.html. Accessed October 18th, 2017.
Definition / general
Microscopic (histologic) images

Images hosted on PathOut server:


Peripheral blood:

Post radiochemotherapy and splenectomy
for Hodgkin disease, has hypogranular neutrophil
with pseudo-Pelger-Huet nucleus,
marked poikilocytosis of erythrocytes


Bone marrow smear:

Large erythroid precursors with lobulated nuclei and karyorrhexis


Stains:

PAS+ erythroid precursors in bone marrow smear

Molecular / cytogenetics description
  • At least 8 alternative genetic pathways
  • Either Class I mutations (activating mutations of genes in tyrosine kinase RAS / BRAF pathway, leading to increased cell proliferation), Class II mutations (inactivating mutations of genes encoding hematopoietic transcription factors, causing disturbed cell proliferation) or inactivating mutations of p53 gene (Hematology Am Soc Hematol Educ Program 2007;392)
Additional references